Reversible Monoacylglycerol Lipase (MAGL) Inhibitors for Neurodegenerative Pathologies and Tumour Treatment
A new class of monoacylglycerol lipase (MAGL) inhibitors distinguished by reversible and powerful mechanism of action
Published: 24th November 2022

Patents
IP Status
- Patented
- Know-how based
Seeking
- Commercial partner
- Licensing
- Seeking investment
- Development partner